Skip to content

Trial · Interventional

Active, not recruitingPhase 3Registry data

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Short name TRIUMPH-9

NCTNCT07357415 (opens ClinicalTrials.gov in a new tab)Other id27795Other idJ1I-MC-GZQL
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Active, not recruiting
Phase
Phase 3
Enrollment
600 participants (estimated)
Sponsor
Eli Lilly and Company · Industry
Design
Randomized · Double masking
Countries
3 countries

United States, Argentina, Canada

Start
24 Jan 2026
Primary completion
Oct 2028 (estimated)
Completion
Nov 2028 (estimated)
First posted
22 Jan 2026
Last update posted
9 Jun 2026
Conditions
Obesity · Overweight

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2026202720282029
  1. Ph 3

    TRIUMPH-9

    NCT07357415

    24 Jan 2026 to est. Nov 2028

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.

Interventions

  • RetatrutideDrug

Arms3

  • Experimental

    Retatrutide Dose Escalation 1

    Participants will receive retatrutide subcutaneously (SC)

  • Experimental

    Retatrutide Dose Escalation 2

    Participants will receive retatrutide SC

  • Experimental

    Retatrutide Dose Escalation 3

    Participants will receive retatrutide SC

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Percent Change from Baseline in Body Weight

    Time frame · Baseline, Week 104

Secondary outcomes(7)

  1. Change from Baseline in Waist Circumference

    Time frame · Baseline, Week 104

  2. Percent Change from Baseline in Triglycerides

    Time frame · Baseline, Week 104

  3. Change from Baseline in Systolic Blood Pressure

    Time frame · Baseline, Week 104

  4. Percent Change from Baseline in High Sensitivity C-Reactive Protein

    Time frame · Baseline, Week 104

  5. Change from Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-Lite-CT) Total Score

    Time frame · Baseline, Week 104

  6. Overall Treatment Satisfaction with Medication for Obesity (TS-MO) Scores

    Time frame · Week 104

  7. Pharmacokinetics (PK): Steady state Average Trough PK Concentration

    Time frame · Baseline through Week 104

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Have a Body Mass Index (BMI) at screening * ≥ 30 kilogram per square meter (kg/m2) OR * ≥ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease * Have at least one unsuccessful attempt to lose weight by dieting Exclusion Criteria: * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have type 1 diabetes or type 2 diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening: * heart attack * stroke * hospitalization for unstable angina or heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

PepBank is a research reference. Talk to a doctor before you use any peptide.